Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis.

Pooled analysis in a fixed-effects model revealed borderline significance between groups (HR = 0.87, 95% CI: 0.75–1.00, p = 0.05, Fig. 2B ).

also in 4,352 other papers

Subgroup analysis As the initial outcome of OS was borderline significant (p = 0.05), we further analysed OS in two subgroups: SL (S-1 plus leucovorin) and non-SL, depending on the regimen of S-1-based combination therapy, two trials from China and Japan were allocated into the SL group.

also in 6,822 other papers

OS also showed a 0.7-month increase in the S-1-based combination therapy group, although this was only of borderline significance.

also in 1,681 other papers